|
Nanovibronix, Inc. (NAOV) DCF -Bewertung
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
NanoVibronix, Inc. (NAOV) Bundle
Optimieren Sie Ihre Analyse und verbessern Sie die Präzision mit unserem (NAOV) DCF -Taschenrechner! Ausgestattet mit echten Daten von Nanovibronix, Inc. und anpassbaren Annahmen ermöglichen Sie, dass Sie wie ein erfahrener Investor prognostizieren, analysieren und beurteilen (NAOV) beurteilen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .5 | .6 | 1.7 | .8 | 2.3 | 3.2 | 4.5 | 6.3 | 8.9 | 12.5 |
| Revenue Growth, % | 0 | 17.55 | 172.07 | -55.63 | 203.59 | 40.48 | 40.48 | 40.48 | 40.48 | 40.48 |
| EBITDA | -5.7 | -4.2 | -14.2 | -5.0 | -3.4 | -3.2 | -4.5 | -6.3 | -8.9 | -12.5 |
| EBITDA, % | -1083.96 | -668.06 | -840.59 | -666.49 | -150.46 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 0.75472 | 0.32103 | 0.11799 | 0.13298 | 0.04380201 | 0.2741 | 0.2741 | 0.2741 | 0.2741 | 0.2741 |
| EBIT | -5.7 | -4.2 | -14.3 | -5.0 | -3.4 | -3.2 | -4.5 | -6.3 | -8.9 | -12.5 |
| EBIT, % | -1084.72 | -668.38 | -840.71 | -666.62 | -150.5 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 1.3 | 7.1 | 7.7 | 2.7 | 3.3 | 3.2 | 4.5 | 6.3 | 8.9 | 12.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .1 | .3 | .1 | .4 | .6 | .8 | 1.1 | 1.6 | 2.2 |
| Account Receivables, % | 24.53 | 14.93 | 15.58 | 14.49 | 18.62 | 17.63 | 17.63 | 17.63 | 17.63 | 17.63 |
| Inventories | .1 | .1 | .2 | 2.2 | 2.7 | 1.6 | 2.3 | 3.2 | 4.6 | 6.4 |
| Inventories, % | 22.83 | 23.27 | 10.32 | 289.23 | 119.67 | 51.29 | 51.29 | 51.29 | 51.29 | 51.29 |
| Accounts Payable | .1 | .1 | .1 | .1 | .1 | .4 | .6 | .9 | 1.2 | 1.7 |
| Accounts Payable, % | 24.34 | 23.11 | 5.13 | 8.78 | 6.04 | 13.48 | 13.48 | 13.48 | 13.48 | 13.48 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 0 | -0.32103 | -0.17699 | -0.39894 | -0.04380201 | -0.18815 | -0.18815 | -0.18815 | -0.18815 | -0.18815 |
| Tax Rate, % | -0.78762 | -0.78762 | -0.78762 | -0.78762 | -0.78762 | -0.78762 | -0.78762 | -0.78762 | -0.78762 | -0.78762 |
| EBITAT | -5.7 | -4.2 | -14.3 | -5.0 | -3.5 | -3.2 | -4.5 | -6.3 | -8.9 | -12.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -5.9 | -4.2 | -14.5 | -6.9 | -4.3 | -2.0 | -5.2 | -7.3 | -10.3 | -14.5 |
| WACC, % | 51.74 | 51.86 | 51.86 | 51.86 | 51.86 | 51.83 | 51.83 | 51.83 | 51.83 | 51.83 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -9.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -15 | |||||||||
| Terminal Value | -30 | |||||||||
| Present Terminal Value | -4 | |||||||||
| Enterprise Value | -13 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | -10 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | -5.58 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real NanoVibronix, Inc. (NAOV) financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
- Forecast Flexibility: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe how your inputs affect NanoVibronix, Inc. (NAOV)’s valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step guidance.
Key Features
- 🔍 Real-Life NAOV Financials: Pre-filled historical and projected data for NanoVibronix, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate NanoVibronix’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize NanoVibronix’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered NanoVibronix data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for NanoVibronix's intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for NanoVibronix, Inc. (NAOV)?
- Accurate Data: Utilize real NanoVibronix financials for trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the field.
- User-Friendly: An intuitive design and guided instructions make it accessible for all users.
Who Should Use This Product?
- Healthcare Professionals: Enhance patient treatment plans with innovative ultrasound technology.
- Researchers: Utilize advanced data to explore the efficacy of non-invasive therapies.
- Investors: Evaluate potential growth and market strategies for NanoVibronix, Inc. (NAOV).
- Medical Device Analysts: Optimize analysis processes with tailored models for product performance.
- Small Business Owners in Healthcare: Understand how emerging technologies impact patient care and market trends.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for NanoVibronix, Inc. (NAOV).
- Real-World Data: NanoVibronix's historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to NanoVibronix, Inc. (NAOV).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.